

The role of aneuploidy in the evolution of cancer drug resistance

Remus Stana¹, Uri Ben-David², Daniel B. Weissman³, and Yoav Ram^{1,*}

¹School of Zoology, Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel

²Department of Human Molecular Genetics and Biochemistry, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

³Department of Physics, Emory University, Atlanta, GA

*Corresponding author: yoav@yoavram.com

June 21, 2023

Abstract

12 Introduction

Aneuploidy in cancer. Chromosomal instability (CIN) is the mitotic process in which cells suffer from chromosome mis-segregation that leads to aneuploidy, where cells are characterized by structural changes of the chromosomes and copy number alterations (Schukken and Fojer, 2018). Interestingly, aberrations in chromosome copy number have been shown to allow cancer cells to survive under stressful conditions such as drug therapy. Indeed, cancer cells are often likely to be aneuploid, and aneuploidy is associated with poor patient outcomes (Ben-David and Amon, 2020).

The role of chromosomal instability (CIN) in the emergence of cancer has been studied extensively in the past decades (Christine et al., 2018, Komarova et al., 2003, Michor et al., 2005, Nowak et al., 2002, Pavelka et al., 2010, Zhu et al., 2018). One hypothesis is that CIN facilitates tumor genesis by accelerating the removal of tumor suppression genes (TSG) and subsequent appearance of cancer. The deletion of tumor suppression genes can happen in two ways: two point mutations deleting both alleles of the TSG (assuming a diploid genotype), or one point mutation and one chromosomal loss event. Initial theoretical studies have shown that aneuploidy can have a significant role in the deletion of the the tumor suppressing genes when compared to two consecutive point mutations (Komarova et al., 2008, 2003, Michor et al., 2005, Nowak et al., 2002). However, when taking into account that the appearance of aneuploidy requires a mutation to trigger CIN, the probability that CIN precedes tumor genesis is highly unlikely.

Evolutionary rescue. Populations adapted to a certain environment are vulnerable to environmental changes, which might cause extinction of the population. Examples of such environmental changes include climate change, invasive species or the onset of drug therapies. Adaptation is a race against time as the population size decreases in the new environment (Tanaka and Wahl, 2022). *Evolutionary rescue* is the process where the population acquires a trait that increases fitness in the new environment such that extinction is averted. It is mathematically equivalent to the problem of crossing of fitness valley (Weissman et al., 2009, 2010). There are three potential ways for a population to survive environmental change: migration to a new habitat similar to the one before the onset of environmental change (Cobbold and Stana, 2020); adaptation by phenotypic plasticity without genetic modification (Carja and Plotkin, 2017, 2019, Levien et al., 2021); and adaptation through genetic modifications, e.g., mutation (Uecker and Hermisson, 2011, 2016, Uecker et al., 2014).

Models of evolutionary rescue usually assume that the fitness of the wildtype and mutant are homogeneous in time. An exception was given by Marrec and Bitbol (2020), who modeled the fitness of the wildtype and mutant as time dependent. Additionally, Uecker and Hermisson (2011) investigated the probability of fixation of a beneficial mutation in a variable environment with arbitrary time-dependent selection coefficient and population size. Most models focus on the probability that at least one mutation rescues the population. How multiple mutations contribute to the survival of the population is less explored, but Wilson et al. (2017) have shown that evolutionary rescue is significantly enhanced by soft selective sweeps when multiple mutations contribute. Evolutionary rescue that requires two successive mutations has been investigated using diffusion approximation by Martin et al. (2013).

Methods

52 Evolutionary model

We follow the number of cancer cells that have one of three different genotypes at time t : wildtype, w_t ; aneuploid, a_t ; and mutant, m_t . These cells divide and die with rates λ_k and μ_k (for $k = w, a, m$). The difference between the division and death rate is $\Delta_k = \lambda_k - \mu_k$. We assume the population of cells is under a strong stress, such as drug therapy, to which the wildtype genotype is susceptible and

therefore $\Delta_w < 0$, whereas the mutant is resistant to the stress, $\Delta_m > 0$. We analyze three scenarios:
 58 in the first, aneuploid cells are partially resistant, $\Delta_m > \Delta_a > 0$; in the second, aneuploid cells are
 tolerant, $0 > \Delta_a > \Delta_w$ (see Brauner et al., 2016, for the distinction between susceptible, resistant,
 60 and tolerant); in the third, aneuploid cells are non-growing or "barely growing", that is, either slightly
 tolerant or slightly resistant, such that $\Delta_a \approx 0$, in a sense that we will make more precise. Wildtype
 62 cells may missegregate to become aneuploids at rate u . Both aneuploid and wildtype cells may mutate
 to become mutants at rate v (Figure 1).

64 Stochastic simulations

Simulations are performed using a *Gillespie algorithm* (Gillespie, 1976, 1977) implemented in Python
 66 (Van Rossum and Others, 2007). The simulation monitors the number of cells of each type: wildtype,
 aneuploid, and mutant. The wildtype population initially consists of w_0 cells, whereas the other cell
 68 types are initially absent.

The state of the stochastic system at time t is represented by the triplet (w_t, a_t, m_t) . The following
 describes the events that may occur (right column), the rates at which they occur (middle column),
 and the effect these events have on the state (Figure 1):

$(+1, 0, 0) :$	$\lambda_w w_t$	(birth of wildtype cell) ,
$(-1, 0, 0) :$	$\mu_w w_t$	(death of wildtype cell) ,
$(-1, +1, 0) :$	$u w_t$	(wildtype cell becomes aneuploid) ,
$(-1, 0, +1) :$	$v w_t$	(wildtype cell becomes mutant) ,
$(0, +1, 0) :$	$\lambda_a a_t$	(birth of aneuploid cell) ,
$(0, -1, 0) :$	$\mu_a a_t$	(death of aneuploid cell) ,
$(0, -1, +1) :$	$v a_t$	(aneuploid cell becomes mutant) ,
$(0, 0, +1) :$	$\lambda_m m_t$	(birth of mutant cell) ,
$(0, 0, -1) :$	$\mu_m m_t$	(death of mutant cell) .

Each iteration of the simulation loop starts with computing the rates ν_j of each event j . We then
 draw the time until the next event, Δt , from an exponential distribution whose rate parameter is the
 sum of the rates of all events, such that $\Delta t \sim \text{Exp}(\sum_j \nu_j)$. Then, we randomly determine which event
 occurred, where the probability for event j is $p_j = \nu_j / \sum_i \nu_i$. Finally, we update the number of cells of
 each type according to the event that occurred and update the time from t to $t + \Delta t$. We repeat these
 iterations until either the population becomes extinct (the number of cells of all types is zero) or the
 number of mutant cells is high enough so that its extinction probability is $< 0.1\%$, that is until

$$m_t > \left\lceil \frac{3 \log 10}{\log \left(\frac{\lambda_m}{\mu_m} \right)} \right\rceil + 1.$$

τ -leaping. When simulations are slow (e.g. due to large population size), we utilize τ -leaping
 70 (Gillespie, 2001), where change in number of cells of genotype i in a fixed time interval Δt is
 Poisson distributed with mean $\nu_i \Delta t$. If the change in number of cells is negative and larger then the
 72 subpopulation size then the subpopulation size is updated to be zero.

Density-dependent growth. In our analysis we assume that lineages produced by cells from the
 initial population divide and die independently of each other, which may be unrealistic, as cells
 usually compete for resources. A more realistic model includes competition for limited resources and
 spatial structure, which may play an important role in the development of cancer (e.g., Martens et al.,

2011). To simulate birth and death rates that depend on the number of cells in the population, we transform the rates of division and death to the following:

$$\begin{aligned}\lambda'_w &= \lambda_w, \\ \mu'_w &= \mu_w, \\ \lambda'_a &= C_1 + (\lambda_a - \mu_a) \left(1 - \frac{w + a + m}{K}\right), \\ \mu'_a &= C_1, \\ \lambda'_m &= C_2 + (\lambda_m - \mu_m) \left(1 - \frac{w + a + m}{K}\right), \\ \mu'_m &= C_2,\end{aligned}$$

where $C_1, C_2 > 0$ are constants and K is the maximum carrying capacity.

74 Code and data availability.

All source code is available online at <https://github.com/yoavram-lab/EvolutionaryRescue>.

76 Results

Evolutionary rescue probability

78 In our model, *evolutionary rescue* occurs when resistant cells appear and fixate ($m_t \gg 1$) in the
 80 population before the population becomes extinct ($w_t = a_t = m_t = 0$). Aneuploidy may contribute
 to evolutionary rescue by either preventing (when $\Delta_a > 0$) or delaying (when $0 > \Delta_a > \Delta_w$) the
 extinction of the population before mutant cells appear and fixate.

To estimate the rescue probability p_{rescue} , we assume independence between clonal lineages starting from an initial population of N wildtype cells (we check the effect of density-dependent growth on our results below). Thus, the rescue probability is given by

$$p_{\text{rescue}} = 1 - (1 - p_w)^N \quad (2a)$$

$$\approx 1 - e^{-Np_w}, \quad (2b)$$

82 where p_w is the probability that the lineage of a single wild-type cell avoids extinction, and the
 approximation $(1 - p_w) \approx e^{-p_w}$ assumes that p_w (but not Np_w) is small.

84 In the Appendix below, we use the theory of multi-type branching processes to find approximate
 expressions eqs. (23), (29) and (32) for p_w in different regimes. Substituting these into eq. (2b), we
 86 find that the rescue probability can be approximated by

$$p_{\text{rescue}} \approx \begin{cases} 1 - \exp \left[\frac{N}{\Delta_w - u - v} \left(v \frac{\Delta_m}{\lambda_m} + \frac{u(\Delta_a - v)}{2\lambda_a} + u \sqrt{\frac{v\Delta_m}{\lambda_a\lambda_m}} \right) \right], & 4\lambda_a v p_m > (\Delta_a - v)^2, \\ 1 - \exp \left[\frac{v\Delta_m N}{\lambda_m \Delta_w} \left(1 - \frac{u}{\Delta_a} \right) \right], & \Delta_a < 0 \quad \text{and} \quad 4\lambda_a v p_m < (\Delta_a - v)^2, \\ 1 - \exp \left[\frac{N}{\Delta_w} \left(\frac{u\Delta_a}{\lambda_a} + \frac{uv\Delta_m}{\lambda_m \Delta_a} + \frac{v\Delta_m}{\lambda_m} \right) \right], & \Delta_a > 0 \quad \text{and} \quad 4\lambda_a v p_m < (\Delta_a - v)^2. \end{cases} \quad (3)$$

88 [Need to explain intuitively what all this means.](#)

These approximations accurately match full stochastic simulations (Figures 2 to 4).

90 **Density-dependent growth** In our analysis we used branching processes, which assume that growth
(division and death) are density-independent. However, growth may be limited by resources (oxygen,
92 nutrients, etc.) and therefore depend on cell density. We therefore performed stochastic simulations of
a logistic growth model with carrying capacity K (Methods). We find that our approximations agree
94 with results of simulations with density-dependent growth for biologically relevant parameter values
(Figure 4).

96 [Need to explain why.](#)

Standing vs. de-novo genetic variation In the above we assumed that upon beginning of drug
98 therapy, the initial tumor consisted entirely of wildtype cells. However, aneuploid cells are likely
generated even before onset of treatment at some rate $\tilde{u} \leq u$ (because the treatment itself may promote
100 generation of aneuploid cells REF), which are likely to have a deleterious effect (REF). But if the
number of cells in the tumor N is large, as expected if drug treatment is applied, there may already be
102 a fraction $f = \tilde{u}/s$ of aneuploid cells in the population, where s is the cost of aneuploidy (REF).

In this scenario, the probability p_{SGV} of evolutionary rescue via standing genetic variation, that is,
by cells with aneuploidy from the initial population is:

$$p_{\text{SGV}} = 1 - (1 - p_a)^{fN} \approx 1 - e^{-fNp_a}.$$

Here p_a is the probability that a lineage started by an aneuploid cell avoids extinction; see (EQUATION)
in the Appendix for its value. The total probability of evolutionary rescue is given by

$$\begin{aligned} p_{\text{rescue}} &= p_{\text{SGV}} + (1 - p_{\text{SGV}}) p_{\text{de novo}} \\ &= 1 - \exp\left(-[(1 - f)p_w + fp_a]N\right). \end{aligned} \quad (4)$$

The fraction of cases in which the population is rescued by pre-existing aneuploid cells (i.e.,
104 standing genetic variation) is given by $F(f) = \frac{p_{\text{SGV}}}{p_{\text{total}}}$ (Figure 5).

Effect of aneuploidy on evolutionary rescue

106 To determine the extent to which aneuploidy may affect evolutionary rescue, we define H to be the
ratio of the rescue probability with aneuploidy ($u > 0$) and the rescue probability without aneuploidy
108 ($u = 0$):

$$H \equiv \frac{p_{\text{rescue}}(u > 0)}{p_{\text{rescue}}(u = 0)}. \quad (5)$$

110 Plugging in our approximations from eq. (2a), we have

$$H \approx \begin{cases} \frac{1 - \exp\left[\frac{N}{\Delta_w - u - v} \left(v \frac{\Delta_m}{\lambda_m} + \frac{u(\Delta_a - v)}{2\lambda_a} + u \sqrt{\frac{v\Delta_m}{\lambda_a \lambda_m}}\right)\right]}{1 - \exp\left[\frac{vN\Delta_m}{(\Delta_w - v)\lambda_m}\right]}, & 4\lambda_a v p_m \gg (\Delta_a - v)^2, \\ \frac{1 - \exp\left[\frac{v\Delta_m N}{\lambda_m \Delta_w} \left(1 - \frac{u}{\Delta_a}\right)\right]}{1 - \exp\left(\frac{v\Delta_m N}{\lambda_m \Delta_w}\right)}, & \Delta_a < 0 \text{ and } 4\lambda_a v p_m \ll (\Delta_a - v)^2, \\ \frac{1 - \exp\left[\frac{N}{\Delta_w} \left(\frac{u\Delta_a}{\lambda_a} + \frac{uv\Delta_m}{\lambda_m \Delta_a} + \frac{v\Delta_m}{\lambda_m}\right)\right]}{1 - \exp\left[\frac{v\Delta_m N}{\lambda_m \Delta_w}\right]}, & \Delta_a > 0 \text{ and } 4\lambda_a v p_m \ll (\Delta_a - v)^2. \end{cases} \quad (6)$$

112 [These expressions are impenetrable. Need to be simplified and interpreted.](#)

Aneuploidy always increases the probability of rescue ($H > 1$). We find that the rescue ratio
114 increase with the aneuploidy growth rate Δ_a , because the better aneuploid cells are in growth, the
better they are at directly rescuing the population (when they provide partial resistance) or avoiding

116 extinction long enough to acquire full resistance (when they provide tolerance). However, the rescue
 118 decreases with the wildtype growth rate Δ_w , because the better the wildtype is at growth, the less is
 120 depends on aneuploidy for rescue or delay, and the more likely it is to directly produce mutant cells,
 122 rather than relying on aneuploid cells for producing mutant cells (Figure 6). The effect of the initial
 tumor size N is the similar to that of the wildtype growth rate. If the tumor is sufficiently large, then
 even in the absence of aneuploidy rescue is almost certain to occur, and therefore aneuploidy has only
 a negligible additional effect.

Evolutionary rescue time

124 Even evolutionary rescue occurs, it may take a long time; therefore, it is crucial to estimate the mean
 waiting time for rescue and the effect aneuploidy may have on it. We therefore calculate the mean time
 126 for the appearance of the first mutant that rescues the cell population. This can occur either through the
 evolutionary trajectory *wildtype* \rightarrow *mutant* or through the trajectory *wildtype* \rightarrow *aneuploid* \rightarrow
 128 *mutant*. We start with the former.

Assuming no aneuploidy ($u = 0$), we define T_1 to be the time at which the first mutant cell appears
 130 that will avoid extinction and will therefore rescue the population. Note that if extinction occurs, that
 is $m_\infty = 0$, then it is implied that $T_1 = \infty$, and vice versa if $T_1 < \infty$ then $m_\infty > 0$.

132 The number of successful mutants generated until time t can be approximated by an inhomogeneous
 Poisson process with rate $R(t) = up_a w_t$, where $w_t = Ne^{\Delta_w t}$ is the number of wildtype cells at time t .
 134 Note that

$$\int_0^t R(z) dz = up_a N \frac{\exp[\Delta_w t] - 1}{\Delta_w} \approx up_a N t, \quad (7)$$

136 by integrating the exponential and because $\frac{\exp[\Delta_w t] - 1}{\Delta_w} = \frac{1 + \Delta_w t + O(t^2) - 1}{\Delta_w} = t + O(t^2)$. The probability
 density function of T_1 is thus $R(t) \exp\left(-\int_0^t R(z) dz\right)$. Therefore, the probability density function of
 138 $(T_1 | T_1 < \infty)$ is $f_1(t) = \frac{R(t) \exp\left(-\int_0^t R(z) dz\right)}{p_{\text{rescue}}}$.

140 We are interested in the mean conditional time, $\tau_1 = \mathbb{E}[T_1 | T_1 < \infty]$, which is given by

$$\tau_1 = \int_0^\infty t f_1(t) dt = \frac{\int_0^\infty t R(t) \exp\left(-\int_0^t R(z) dz\right) dt}{p_{\text{rescue}}} = \frac{\int_0^\infty \exp\left(-\int_0^t R(z) dz\right) dt}{p_{\text{rescue}}} \quad (8)$$

after applying integration by parts. Therefore, plugging eqs. (2b) and (7) in eq. (11), the probability
 density function of T_1 is given by:

$$f_{T_1}(t_1) = R(t_1) e^{-\int_0^{t_1} R(t) dt}. \quad (9)$$

As a result, the time T_1 conditional on evolutionary rescue is given by:

$$f_{T_1}(t_1 | m_{t \rightarrow \infty} \neq 0) = \frac{R(t_1) e^{-\int_0^{t_1} R(t) dt}}{1 - (1 - p_w)^N}. \quad (10)$$

The expectation of T_1 is:

$$\tau_1 = \mathbb{E}[T_1] = \frac{\int_0^\infty e^{-\int_0^\tau R(t) dt} d\tau}{1 - (1 - p_w)^N} = \frac{\int_0^\infty e^{-u N p_a \frac{e^{\Delta_w \tau} - 1}{\Delta_w}} d\tau}{1 - (1 - p_w)^N}. \quad (11)$$

The fraction in the exponential of the integrand in (11) can be approximated as:

$$\frac{e^{\Delta_w \tau} - 1}{\Delta_w} = \frac{1 + \Delta_w \tau + O(\tau^2) - 1}{\Delta_w} = \tau + O(\tau^2).$$

As a result, the mean time τ_1 can be simplified:

$$\tau_1 = \frac{\int_0^\infty \exp(-up_a N t) dt}{1 - e^{-N p_w}} \approx \left(1 + e^{-N p_w}\right) \int_0^\infty e^{-up_a N t} dt = \frac{1 + e^{-N p_w}}{up_a N}, \quad (12)$$

142 where we use the approximation $\left(1 - e^{-N p_w}\right)^{-1} \approx 1 + e^{-N p_w}$ and integrate the exponent. Figure 7
show the agreement between this approximating and simulation results for intermediate and large
144 tumor sizes.

THE REST OF THIS SECTION REQUIRES EDITING BY YOAV

146 When $Nu \gg 1$ the aneuploid population can be assumed to be deterministic and approximated by
the solution to the system of ODEs:

$$148 \quad a_t = \frac{Nu e^{\Delta_w t}}{\Delta_w - \Delta_a} \left[1 - e^{(\Delta_w - \Delta_a)t}\right]. \quad (13)$$

As a result, when $N \gg 1$ the number of successful mutants created by direct mutation or though
150 aneuploidy are an inhomogeneous Poisson processes with the rates:

$$r_1(t) = v p_m \int_0^t a_\tau d\tau = \frac{uv N p_m}{\Delta_w - \Delta_a} \left(\frac{e^{\Delta_w t} - 1}{\Delta_w} - \frac{e^{\Delta_a t} - 1}{\Delta_a} \right), \quad (14)$$

$$r_2(t) = v p_m \int_0^t w_\tau d\tau = v N p_m \frac{e^{\Delta_w t} - 1}{\Delta_w}. \quad (15)$$

For large initial population sizes we can assume that both rescue mutations produced through direct
mutation and aneuploidy are independent and, as a result, they can be merged into a single Poisson
process with rate $(r_1 + r_2)(t)$. Consequently, the mean time to the appearance of the first rescue
mutant is:

$$\tau_2 = \frac{\int_0^\infty e^{-(r_1+r_2)} d\tau}{1 - (1 - p_w)^N} = \frac{\int_0^\infty \exp \left[-\frac{uv N p_m}{\Delta_w - \Delta_a} \left(\frac{e^{\Delta_w \tau} - 1}{\Delta_w} - \frac{e^{\Delta_a \tau} - 1}{\Delta_a} \right) - v N p_m \frac{e^{\Delta_w \tau} - 1}{\Delta_w} \right] d\tau}{1 - (1 - p_w)^N}, \quad (16)$$

which we plot in Figure 7 as a function of the initial population size.

We wish to obtain a simpler formula for τ_2 in an analogous way to (12). For this, we make use of
the following expansions:

$$\begin{aligned} \frac{e^{\Delta_w \tau} - 1}{\Delta_w} &= \frac{1 + \Delta_w \tau + \frac{\Delta_w^2 \tau^2}{2} + O(\tau^3) - 1}{\Delta_w} = \tau + \frac{\Delta_w}{2} \tau^2 + O(\tau^3), \\ \frac{e^{\Delta_a \tau} - 1}{\Delta_a} &= \frac{1 + \Delta_a \tau + \frac{\Delta_a^2 \tau^2}{2} + O(\tau^3) - 1}{\Delta_a} = \tau + \frac{\Delta_a}{2} \tau^2 + O(\tau^3), \end{aligned}$$

which allow us to write:

$$\frac{e^{\Delta_w \tau} - 1}{\Delta_w} - \frac{e^{\Delta_a \tau} - 1}{\Delta_a} \approx \frac{(\Delta_w - \Delta_a) \tau^2}{2}.$$

As a result, the integrand in (16) can be written as:

$$\begin{aligned} &\exp \left[-\frac{uv N p_m}{\Delta_w - \Delta_a} \left(\frac{e^{\Delta_w \tau} - 1}{\Delta_w} - \frac{e^{\Delta_a \tau} - 1}{\Delta_a} \right) - v N p_m \frac{e^{\Delta_w \tau} - 1}{\Delta_w} \right] \approx \exp \left(-uv N p_m \tau^2 - v N p_m \tau \right) \\ &= \exp \left(\frac{v N p_m}{2} \right) \exp \left[-\frac{uv N p_m}{2} \left(\tau + \frac{1}{u} \right) \right]. \end{aligned}$$

Consequently, the mean time τ_2 is obtained to be:

$$\tau_2 \approx [1 + \exp(-Np_w)] \exp\left(\frac{vNp_m}{2u}\right) \frac{\operatorname{erfc}\left(\sqrt{\frac{vNp_m}{2u}}\right)}{\sqrt{\frac{2uvNp_m}{\pi}}}, \quad (17)$$

where erfc is the complementary error function. We plot the expansion (17) in Figure 7 and observe that it is a very good fit for large values of the initial wildtype population size.

If we select only linear terms in the following expansions:

$$\begin{aligned} \frac{e^{\Delta_w \tau} - 1}{\Delta_w} &= \frac{1 + \Delta_w \tau + O(\tau^2) - 1}{\Delta_w} = \tau + O(\tau^2), \\ \frac{e^{\Delta_a \tau} - 1}{\Delta_a} &= \frac{1 + \Delta_a \tau + O(\tau^2) - 1}{\Delta_a} = \tau + O(\tau^2), \end{aligned}$$

we obtain the first order approximation for τ_2 :

$$\tau_2 \approx \left(1 + e^{-Np_w}\right) \int_0^\infty e^{-uNp_m \tau} d\tau = \frac{(1 + e^{-Np_w})}{uNp_m}, \quad (18)$$

which we plot in Figure 7 and observe that it offer as a good a fit to eq. (16) as eq. (17). Additionally, we observe that for large initial wildtype populations sizes direct mutation drives evolutionary rescue while aneuploidy plays a role for intermediate sized tumors. This is consistent with the information obtained from fig. 6 where aneuploidy improves the probability of evolutionary rescue only for small and intermediate values of N .

Contribution of aneuploidy to mean evolutionary rescue time

$$I = \frac{\tau_2}{\tau_1} = \frac{\int_0^\infty \exp\left[-\frac{uvNp_m}{\Delta_w - \Delta_a} \left(\frac{e^{\Delta_w \tau} - 1}{\Delta_w} - \frac{e^{\Delta_a \tau} - 1}{\Delta_a}\right) - vNp_m \frac{e^{\Delta_w \tau} - 1}{\Delta_w}\right] d\tau}{\int_0^\infty e^{-uNp_m \frac{e^{\Delta_w \tau} - 1}{\Delta_w}} d\tau} \times \frac{1 - \left(1 - p_w|_{u=0}\right)^N}{1 - \left(1 - p_w|_{u>0}\right)^N} \quad (19)$$

$$= \frac{\int_0^\infty \exp\left[-\frac{uvNp_m}{\Delta_w - \Delta_a} \left(\frac{e^{\Delta_w \tau} - 1}{\Delta_w} - \frac{e^{\Delta_a \tau} - 1}{\Delta_a}\right) - vNp_m \frac{e^{\Delta_w \tau} - 1}{\Delta_w}\right] d\tau}{\int_0^\infty e^{-vNp_m \frac{e^{\Delta_w \tau} - 1}{\Delta_w}} d\tau} \frac{1}{H}, \quad (20)$$

where H , is the ratio of the probability of evolutionary rescue with and without aneuploidy, defined in eq. (5). We plot eq. (20) in Figure 8 as a function of the initial wildtype population for varying values of the Malthusian fitness of aneuploid cells Δ_a .

Discussion

Evolutionary rescue is the process where the population acquires a trait that increases fitness in the new environment such that extinction is averted. Here, we have modeled a tumor—a population of cancer cells—exposed to drug therapy that causes the cell population to decline towards extinction. The cancer cell population can escape extinction either by a mutation that confers resistance, or by first generating aneuploid cells in which the effect of the drug is diminished, and then producing a mutation that confers full resistance (Figure 1).

Using multitype branching processes, we derived the probability of evolutionary rescue of the population of cancer cells under various scenarios for the effect of aneuploidy, including both tolerance and partial resistance to the drug. We obtained both exact and approximate expressions for the probability of evolutionary rescue. As expected, our analytic results in eq. (2a) show that the probability of evolutionary rescue increases with the initial tumor size N , the wildtype growth rate $\Delta_w = \lambda_w - \mu_w$, and the mutation v and aneuploidy u rates.

When aneuploid cells are partially resistant to the drug ($\Delta_w \ll (\text{SOMETHING} \neq 0) \ll \Delta_a \ll \Delta_m$), evolutionary rescue can be approximated by a one-step evolutionary rescue process where aneuploidy itself rescues the population (Figure 2). When aneuploidy only provides tolerance to the drug ($\Delta_w \ll \Delta_a \ll (\text{SOMETHING} \neq 0) \ll \Delta_m$), it cannot rescue the population. Instead, aneuploidy acts as a *stepping stone* through which the resistant mutant can appear in a more expedient fashion, given that the aneuploid cell population declines slower than the wildtype cell population. In this case, aneuploidy provides two benefits. First, it delays the extinction of the population—providing more time for appearance of the resistance mutations. Second, it increases the population size relative to a wildtype population—providing more cells for generating mutations, i.e., it increases the mutation supply.

We find that aneuploidy can have a significant effect on evolutionary rescue (Figure 6). For example, when aneuploidy cells are "barely-resistant" (they grow at a very low rate, $\Delta_a = 10^{-3}$) the probability of evolutionary rescue is 1000-fold higher with aneuploidy than without it (for parameters previously described in cancer Table 1). Interestingly, aneuploidy is unlikely to contribute to evolutionary rescue in primary tumors, as the number of cells in such tumors ($N > 10^7$) is large enough for the appearance of resistant mutation directly before the extinction of wildtype cells (Figure 6). However, aneuploidy may play a crucial role in evolutionary rescue of secondary tumors, whose size may be below the detection threshold of $\sim 10^7$ (Bozic et al., 2013). Given the fact that the mean time for such secondary tumors to overcome chemotherapy can be of the order of 100 days (Figure 7), this can explain the reappearance of cancer even after initial remission.

We hypothesized that presence of "standing variation"—a subpopulation of aneuploid cancer cells—at the onset of chemotherapy may facilitate evolutionary rescue by reducing the waiting time for the appearance of aneuploid cells. Indeed, we observe that even when a small fraction of the initial tumor is aneuploid, evolutionary rescue is more likely to occur through this existing standing variation, rather than through "de novo" aneuploid cells (Figure 5).

We have assumed that cancer cell lineages are independent of each other. However, this may not be the case, as cancer cells compete for resources (e.g., blood supply). Nevertheless, we find that when the carrying capacity is large our approximation for the probability of evolutionary rescue agrees with results of stochastic simulations with density-dependent growth (Figure 4). Future work may focus on scenarios with small carrying capacity by analysing density-dependent branching processes.

Our model predictions may be tested by experiments (Martin et al., 2013). For example, to study the effects of initial tumor size on the probability of evolutionary rescue, a large culture mass can be propagated from a single cancer cell in permissive conditions and then diluted to a range of starting tumor sizes. Afterwards, these tumors may be exposed to anti-cancer drugs that induces aneuploidy or to saline solution for control. Cell density can then be measured and compared to the predictions of our model.

1 Appendices

Calculation of survival probabilities of single lineages

Here we calculate the *survival probability*, the probability that a lineage descended from a single cell does not become extinct. Let p_w , p_a , and p_m be the survival probabilities of a lineage started by a single wildtype cell, aneuploid cell, or mutant cell, respectively. We will neglect density dependence,

allowing us to treat the lineages as *multitype branching processes* (Harris et al., 1963). The extinction probabilities $1 - p_w$, $1 - p_a$, and $1 - p_m$ then satisfy the equations:

$$\begin{aligned} 1 - p_w &= \frac{\mu_w}{\lambda_w + \mu_w + u + v} + \frac{u}{\lambda_w + \mu_w + u + v} (1 - p_a) + \\ &\quad \frac{\lambda_w}{\lambda_w + \mu_w + u + v} (1 - p_w)^2 + \frac{v}{\lambda_w + \mu_w + u + v} (1 - p_m), \\ 1 - p_a &= \frac{\mu_a}{\lambda_a + \mu_a + v} + \frac{v}{\lambda_a + \mu_a + v} (1 - p_m) + \frac{\lambda_a}{\lambda_a + \mu_a + v} (1 - p_a)^2, \\ 1 - p_m &= \frac{\mu_m}{\lambda_m + \mu_m} + \frac{\lambda_m}{\lambda_m + \mu_m} (1 - p_m)^2. \end{aligned} \tag{21}$$

Rewrite the below in terms of Δk .

The survival probabilities are given by the smallest solution for each quadratic equation (Uecker et al., 2015, Weissman et al., 2009). Therefore we have

$$\begin{aligned} p_w &= \frac{\lambda_w - \mu_w - u - v + \sqrt{(\lambda_w - \mu_w - u - v)^2 + 4\lambda_w(u p_a + v p_m)}}{2\lambda_w}, \\ p_a &= \frac{\lambda_a - \mu_a - v + \sqrt{(\lambda_a - \mu_a - v)^2 + 4\lambda_a v p_m}}{2\lambda_a}, \\ p_m &= \frac{\lambda_m - \mu_m}{\lambda_m}. \end{aligned} \tag{22}$$

Note that the equation for p_w depends on both p_a and p_m , and the equation for p_a depends on p_m . To proceed, we can plug the solution for p_m and p_a into the solution for p_w . We perform this for three different scenarios.

Scenario 1: Aneuploid cells are partially resistant

We first assume that aneuploidy provides partial resistance to drug therapy, $\lambda_a > \mu_a$, and that this resistance is significant, $(\lambda_a - \mu_a - v)^2 > 4\lambda_a v p_m$. We thus rewrite eq. (22) as

$$\begin{aligned} p_w &= \frac{\lambda_w - \mu_w - u - v}{2\lambda_w} \left(1 - \sqrt{1 + \frac{4\lambda_w(v p_m + u p_a)}{(\lambda_w - \mu_w - u - v)^2}} \right), \text{ and} \\ p_a &= \frac{\lambda_a - \mu_a - v}{2\lambda_a} \left(1 + \sqrt{1 + \frac{4\lambda_a v p_m}{(\lambda_a - \mu_a - v)^2}} \right). \end{aligned}$$

Using the quadratic Taylor expansion $\sqrt{1+x} = 1 + x/2 + O(x^2)$ and assuming $u, v \ll 1$, we obtain the following approximation for the survival probability of a population initially consisting of a single wildtype cell,

$$p_w \approx -\frac{v p_m + u p_a}{\lambda_w - \mu_w - u - v} \tag{23}$$

$$\approx -\frac{1}{\lambda_w - \mu_w} \left[\frac{u(\lambda_a - \mu_a)}{\lambda_a} + \frac{uv(\lambda_m - \mu_m)}{\lambda_m(\lambda_a - \mu_a)} + \frac{v(\lambda_m - \mu_m)}{\lambda_m} \right] \tag{24}$$

Second-order approximation. To improve our approximation, we can consider the second term of the Taylor series expansion,

$$\left(1 + \frac{4\lambda_a v p_m}{(\lambda_a - \mu_a - v)^2}\right)^{\frac{1}{2}} = 1 + \frac{2\lambda_a v p_m}{(\lambda_a - \mu_a - v)^2} - \frac{(\lambda_a v p_m)^2}{4(\lambda_a - \mu_a - v)^4} + \dots,$$

which gives us the following approximation,

$$p_a \approx \frac{\lambda_a - \mu_a - v}{\lambda_a} + \frac{v p_m}{\lambda_a - \mu_a - v} - \frac{\lambda_a (v p_m)^2}{8(\lambda_a - \mu_a - v)^3}. \quad (25)$$

We therefore have

$$\begin{aligned} p_w &\approx -\frac{1}{\lambda_w - \mu_w - u - v} \left[\frac{u(\lambda_a - \mu_a - v)}{\lambda_a} + \frac{uv(\lambda_m - \mu_m)}{\lambda_m(\lambda_a - \mu_a - v)} + \frac{v(\lambda_m - \mu_m)}{\lambda_m} - \frac{uv^2\lambda_a(\lambda_m - \mu_m)^2}{8\lambda_m^2(\lambda_a - \mu_a - v)^3} \right] \\ &\approx -\frac{1}{\lambda_w - \mu_w} \left[\frac{u(\lambda_a - \mu_a)}{\lambda_a} + \frac{uv(\lambda_m - \mu_m)}{\lambda_m(\lambda_a - \mu_a)} + \frac{v(\lambda_m - \mu_m)}{\lambda_m} - \frac{uv^2\lambda_a(\lambda_m - \mu_m)^2}{8\lambda_m^2(\lambda_a - \mu_a)^3} \right], \end{aligned} \quad (26)$$

and using $\Delta_k = \lambda_k - \mu_k$, we can write the above equation as

$$p_w \approx -\frac{1}{\Delta_w} \left(\frac{u\Delta_a}{\lambda_a} + \frac{uv\Delta_m}{\lambda_m\Delta_a} + \frac{v\Delta_m}{\lambda_m} - \frac{uv^2\lambda_a\Delta_m^2}{8\lambda_m^2\Delta_a^3} \right). \quad (27)$$

Scenario 2: Aneuploid cells are tolerant.

We now assume that aneuploidy provides tolerance to drug therapy, that is, the number of aneuploid cells significantly declines over time, but at a lower rate than the number of wildtype cells, $\lambda_w - \mu_w < \lambda_a - \mu_a < 0$. We also assume that the decline are significant, $(\lambda_a - \mu_a - v)^2 > 4\lambda_a v p_m$. We rewrite eq. (22) as

$$\begin{aligned} p_w &= \frac{\lambda_w - \mu_w - u - v}{2\lambda_w} \left(1 - \sqrt{1 + \frac{4\lambda_w(v p_m + u p_a)}{(\lambda_w - \mu_w - u - v)^2}} \right), \text{ and} \\ p_a &= \frac{\lambda_a - \mu_a - v}{2\lambda_a} \left(1 - \sqrt{1 + \frac{4\lambda_a v p_m}{(\lambda_a - \mu_a - v)^2}} \right). \end{aligned} \quad (28)$$

Since $u, v \ll 1$, the term in the root can be approximated using a 1st-order Taylor expansion. So, substituting the expressions for p_a and p_m , we have

$$\begin{aligned} p_w &\approx -\frac{v p_m + u p_a}{\lambda_w - \mu_w - u - v} \\ &\approx \frac{1}{\lambda_w - \mu_w - u - v} \left[\frac{uv(\lambda_m - \mu_m)}{\lambda_m(\lambda_a - \mu_a - v)} - \frac{v(\lambda_m - \mu_m)}{\lambda_m} \right] \\ &\approx \frac{v(\lambda_m - \mu_m)}{\lambda_m(\lambda_w - \mu_w)} \left[\frac{u}{(\lambda_a - \mu_a)} - 1 \right] \end{aligned} \quad (29)$$

Scenario 3: Aneuploid cells are non-growing

We now assume that the growth rate of aneuploid cells is close to zero (either positive or negative), such that $(\lambda_a - \mu_a - v)^2 < 4\lambda_a v p_m$. We rewrite eq. (22) as

$$p_a = \frac{\lambda_a - \mu_a - v + 2\sqrt{\lambda_a v p_m} \left(1 + \frac{(\lambda_a - \mu_a - v)^2}{4\lambda_a v p_m}\right)^{\frac{1}{2}}}{2\lambda_a}. \quad (30)$$

Using a following Taylor series expansion

$$\left(1 + \frac{(\lambda_a - \mu_a - v)^2}{4\lambda_a v p_m}\right)^{\frac{1}{2}} = 1 + \frac{(\lambda_a - \mu_a - v)^2}{8\lambda_a v p_m} + \dots,$$

we obtain the approximation

$$\begin{aligned} p_a &\approx \frac{\lambda_a - \mu_a - v + 2\sqrt{\lambda_a v p_m} \left[1 + \frac{(\lambda_a - \mu_a - v)^2}{8\lambda_a v p_m}\right]}{2\lambda_a} \\ &= \frac{\lambda_a - \mu_a - v + 2\sqrt{\lambda_a v p_m} + \frac{(\lambda_a - \mu_a - v)^2}{4\sqrt{\lambda_a v p_m}}}{2\lambda_a} \\ &= \frac{\left(\lambda_a - \mu_a - v + 2\sqrt{\lambda_a v p_m}\right)^2 + 4\lambda_a v p_m}{8\lambda_a \sqrt{\lambda_a v p_m}} \\ &= \frac{4\lambda_a v p_m + 4\lambda_a v p_m \left(1 + \frac{\lambda_a - \mu_a - v}{2\sqrt{\lambda_a v p_m}}\right)^2}{8\lambda_a \sqrt{\lambda_a v p_m}} \\ &= \frac{1}{2\lambda_a} \left(\lambda_a - \mu_a - v + 2\sqrt{\lambda_a v p_m}\right). \end{aligned} \quad (31)$$

Plugging this in eq. (29), the survival probability of a population starting from one wildtype individual is

$$\begin{aligned} p_w &\approx -\frac{1}{\lambda_w - \mu_w - u - v} \left[v \frac{\lambda_m - \mu_m}{\lambda_m} + \frac{u}{2\lambda_a} \left(\lambda_a - \mu_a - v + 2\sqrt{\lambda_a v p_m}\right) \right] \\ &= -\frac{1}{\lambda_w - \mu_w - u - v} \left[v \frac{\lambda_m - \mu_m}{\lambda_m} + \frac{u}{2\lambda_a} (\lambda_a - \mu_a - v) + u \sqrt{\frac{v(\lambda_m - \mu_m)}{\lambda_a \lambda_m}} \right]. \end{aligned} \quad (32)$$

Acknowledgements

This work was supported in part by the Israel Science Foundation (ISF 552/19, YR), the US–Israel Binational Science Foundation (BSF 2021276, YR), Minerva Stiftung Center for Lab Evolution (YR), and the Ela Kodesz Institute for Research on Cancer Development and Prevention (RS).

References

Bakker, B., Schubert, M., Bolhaqueiro, A. C., Kops, G. J., Spierings, D. C. and Fojier, F. (2023), ‘Predicting cin rates from single-cell whole genome sequencing data using an in silico model’, *bioRxiv* pp. 2023–02.

- Ben-David, U. and Amon, A. (2020), ‘Context is everything: aneuploidy in cancer’, *Nature Reviews Genetics* **21**(1), 44–62.
- Bozic, I., Reiter, J. G., Allen, B., Antal, T., Chatterjee, K., Shah, P., Moon, Y. S., Yaquibie, A., Kelly, N., Le, D. T. et al. (2013), ‘Evolutionary dynamics of cancer in response to targeted combination therapy’, *elife* **2**, e00747.
- Brauner, A., Fridman, O., Gefen, O. and Balaban, N. Q. (2016), ‘Distinguishing between resistance, tolerance and persistence to antibiotic treatment’, *Nature Reviews Microbiology* **14**(5), 320–330.
- Carja, O. and Plotkin, J. B. (2017), ‘The evolutionary advantage of heritable phenotypic heterogeneity’, *Scientific reports* **7**(1), 1–12.
- Carja, O. and Plotkin, J. B. (2019), ‘Evolutionary rescue through partly heritable phenotypic variability’, *Genetics* **211**(3), 977–988.
- Christine, J. Y., Regan, S., Liu, G., Alemara, S. and Heng, H. H. (2018), ‘Understanding aneuploidy in cancer through the lens of system inheritance, fuzzy inheritance and emergence of new genome systems’, *Molecular cytogenetics* **11**(1), 1–13.
- Cobbold, C. A. and Stana, R. (2020), ‘Should I stay or should I go: partially sedentary populations can outperform fully dispersing populations in response to climate-induced range shifts’, *Bulletin of Mathematical Biology* **82**(2), 1–21.
- Del Monte, U. (2009), ‘Does the cell number 109 still really fit one gram of tumor tissue?’, *Cell cycle* **8**(3), 505–506.
- Gillespie, D. T. (1976), ‘A general method for numerically simulating the stochastic time evolution of coupled chemical reactions’, *Journal of computational physics* **22**(4), 403–434.
- Gillespie, D. T. (1977), ‘Exact stochastic simulation of coupled chemical reactions’, *The journal of physical chemistry* **81**(25), 2340–2361.
- Gillespie, D. T. (2001), ‘Approximate accelerated stochastic simulation of chemically reacting systems’, *The Journal of chemical physics* **115**(4), 1716–1733.
- Harris, T. E. et al. (1963), *The theory of branching processes*, Vol. 6, Springer Berlin.
- Komarova, N. L., Sadvovsky, A. V. and Wan, F. Y. (2008), ‘Selective pressures for and against genetic instability in cancer: a time-dependent problem’, *Journal of The Royal Society Interface* **5**(18), 105–121.
- Komarova, N. L., Sengupta, A. and Nowak, M. A. (2003), ‘Mutation–selection networks of cancer initiation: tumor suppressor genes and chromosomal instability’, *Journal of theoretical biology* **223**(4), 433–450.
- Levien, E., Min, J., Kondev, J. and Amir, A. (2021), ‘Non-genetic variability in microbial populations: survival strategy or nuisance?’, *Reports on Progress in Physics* **84**(11), 116601.
- Marrec, L. and Bitbol, A.-F. (2020), ‘Adapt or perish: Evolutionary rescue in a gradually deteriorating environment’, *Genetics* **216**(2), 573–583.
- Martens, E. A., Kostadinov, R., Maley, C. C. and Hallatschek, O. (2011), ‘Spatial structure increases the waiting time for cancer’, *New journal of physics* **13**(11), 115014.

- Martin, G., Aguilée, R., Ramsayer, J., Kaltz, O. and Ronce, O. (2013), ‘The probability of evolutionary rescue: towards a quantitative comparison between theory and evolution experiments’, *Philosophical Transactions of the Royal Society B: Biological Sciences* **368**(1610), 20120088.
- Michor, F., Iwasa, Y., Vogelstein, B., Lengauer, C. and Nowak, M. A. (2005), Can chromosomal instability initiate tumorigenesis?, in ‘Seminars in cancer biology’, Vol. 15, Elsevier, pp. 43–49.
- Nowak, M. A., Komarova, N. L., Sengupta, A., Jallepalli, P. V., Shih, I.-M., Vogelstein, B. and Lengauer, C. (2002), ‘The role of chromosomal instability in tumor initiation’, *Proceedings of the National Academy of Sciences* **99**(25), 16226–16231.
- Nowak, M. A., Michor, F., Komarova, N. L. and Iwasa, Y. (2004), ‘Evolutionary dynamics of tumor suppressor gene inactivation’, *Proceedings of the National Academy of Sciences* **101**(29), 10635–10638.
- Pavelka, N., Rancati, G. and Li, R. (2010), ‘Dr Jekyll and Mr Hyde: role of aneuploidy in cellular adaptation and cancer’, *Current opinion in cell biology* **22**(6), 809–815.
- Schukken, K. M. and Foijer, F. (2018), ‘Cin and aneuploidy: different concepts, different consequences’, *Bioessays* **40**(1), 1700147.
- Tanaka, M. M. and Wahl, L. M. (2022), ‘Surviving environmental change: when increasing population size can increase extinction risk’, *Proceedings of the Royal Society B* **289**(1976), 20220439.
- Uecker, H. and Hermisson, J. (2011), ‘On the fixation process of a beneficial mutation in a variable environment’, *Genetics* **188**(4), 915–930.
- Uecker, H. and Hermisson, J. (2016), ‘The role of recombination in evolutionary rescue’, *Genetics* **202**(2), 721–732.
- Uecker, H., Otto, S. P. and Hermisson, J. (2014), ‘Evolutionary rescue in structured populations’, *The American Naturalist* **183**(1), E17–E35.
- Uecker, H., Setter, D. and Hermisson, J. (2015), ‘Adaptive gene introgression after secondary contact’, *Journal of mathematical biology* **70**, 1523–1580.
- Van Rossum, G. and Others (2007), Python Programming Language., in ‘USENIX Annu. Tech. Conf.’.
- Weissman, D. B., Desai, M. M., Fisher, D. S. and Feldman, M. W. (2009), ‘The rate at which asexual populations cross fitness valleys’, *Theoretical population biology* **75**(4), 286–300.
- Weissman, D. B., Feldman, M. W. and Fisher, D. S. (2010), ‘The rate of fitness-valley crossing in sexual populations’, *Genetics* **186**(4), 1389–1410.
- Wilson, B. A., Pennings, P. S. and Petrov, D. A. (2017), ‘Soft selective sweeps in evolutionary rescue’, *Genetics* **205**(4), 1573–1586.
- Zhu, J., Tsai, H.-J., Gordon, M. R. and Li, R. (2018), ‘Cellular stress associated with aneuploidy’, *Developmental cell* **44**(4), 420–431.

	Name	Value	Units
N	Initial tumor size	$10^7 - 10^9$	cells
λ_w	Wildtype division rate	0.14	1/days
μ_w	Wildtype death rate	0.17	1/days
λ_a	Aneuploid division rate*	0.14	1/days
μ_a	Aneuploid death rate*	0.13 – 0.17	1/days
λ_m	Mutant division rate	0.14	1/days
μ_m	Mutant death rate	0.13	1/days
$\Delta_k \equiv \lambda_k - \mu_k$	1/days	Growth rate of type k cells, for $k = w, a, m$	
u	Missegregation rate	$10^{-3} - 10^{-2}$	1/cell division
v	Mutation rate	$10^{-7} - 10^{-9}$	1/gene/cell division

Table 1: Model parameters. Aneuploid birth rate λ_a is set to the same value as the wildtype and mutant birth rates, λ_w and λ_m . Aneuploid death rate μ_a is set to an intermediate value between the wildtype and mutant death rates, μ_w and μ_m .




Figure 1: Model illustration. (A) A population of cancer cells is composed of wildtype, aneuploid, and mutant cells, which divide with rates λ_w , λ_a , and λ_m and die at rates μ_w , μ_a , and μ_m , respectively. Wildtype cells can become aneuploid at rate u . Both aneuploid and wildtype cells can acquire a beneficial mutation with rate v . Color denotes the relative growth rates of the three genotypes such that $\lambda_w - \mu_w < \lambda_a - \mu_a < \lambda_m - \mu_m$. (B) The wildtype and the mutant are susceptible and resistant, respectively, to the drug. The aneuploid may be tolerant, non-growing, or partially resistant.




Figure 2: Evolutionary rescue probability with partially resistant or tolerant aneuploid cells. Rescue probability is very high when aneuploidy provides partial resistance ($\lambda_a = 0.01$), in an initially small tumor (**Aleft**, $N = 10^4$) and even more so in an initially large tumor (**Aright**, $N = 10^8$). When aneuploidy provides tolerance (**Bleft**, $N = 10^4$; **Bright**, $N = 10^8$), the rescue probability is much lower. In both scenarios, rescue probability increase with both the wildtype growth rate (x-axis) and the aneuploidy growth rate (colors). Markers represent simulation results with 95% CI; solid and dashed lines for the exact formula (eq. (22) in eq. (2a)); dashed lines for the approximate formula (eq. (3)), demonstrating that they all agree. Parameters: division rate $\lambda_w = \lambda_a = \lambda_m = 0.14$ (so that growth rate changes due to variable death rate); mutant death rate $\mu_m = 0.13$ (so that mutant growth rate $\Delta_m = 0.01$); aneuploidy rate $u = 10^{-2}$; mutation rate $v = 10^{-7}$.




Figure 3: Evolutionary rescue probability with tolerant or non-growing aneuploid cells. Rescue probability grows with the aneuploid growth rate Δ_a (x-axis), and is much higher in an initially large tumor than in a small one ((A) $N = 10^4$; (B) $N = 10^8$). Markers for simulation results with 95% CI; solid lines for the exact formula (eq. (22) in eq. (2a)); dashed lines for the approximate formula (eq. (3)). The approximation agrees with the simulation and exact solution when the initial tumor size is large (panel B). When the tumor size is small (panel A), we switch between the approximation for tolerant and for non-growing aneuploid cells; the switch occurs at $\Delta_a^* = 2vp_m + v + 2\sqrt{vp_m(vp_m + \mu_a + v)}$. Parameters: $\lambda_w = \lambda_a = \lambda_m = 0.14$; $\mu_m = 0.13$; $u = 10^{-2}$; $v = 10^{-7}$.




Figure 4: Evolutionary rescue probability for variable initial tumor size. (A) Comparison of simulation results (markers with 95% CI, too small to appear with 10^5 simulations per marker), the exact formula (blue line, eq. (22) in eq. (2a)) and the approximate formula (orange line, eq. (3)). (B) Comparison of results of simulations with density-dependent growth (markers with 95% CI) and the exact formula (blue line, eq. (22) in eq. (2a)) with maximum carrying capacity $K = 10^9$. Parameters: $\lambda_w = \lambda_a = \lambda_m = 0.14$; $\mu_w = 0.17$; (A) $\mu_a = 0.15$, (B) $\mu_a = 0.135$; $\mu_m = 0.13$; $u = 10^{-2}$; $v = 10^{-7}$.




Figure 5: Effect of standing variation on evolutionary rescue. In aneuploid cells already exist in the population at the onset of drug therapy as standing genetic variation, then evolutionary rescue is more likely... Parameters: $\lambda_w = \lambda_a = \lambda_m = 0.14$; $\mu_w = 0.17$; $\mu_a = 0.145$; $\mu_m = 0.13$; $u = 10^{-2}$; $v = 10^{-7}$.




Figure 6: Effect of aneuploidy on evolutionary rescue. The ratio of rescue probability with and without aneuploid (H , eq. (6)) increases with the aneuploid growth rate (colors) and decreases with the wildtype growth rates and initial tumor size (x-axes), except for large tumors where the ratio converges to unity. **(A-left, A-right)** Aneuploidy provides partial resistance. **(B-left, B-right)** Aneuploidy provides tolerance. Solid and dashed lines apply p_{rescue} from the exact formula of (eq. (22) in eq. (2a)); dashed lines apply p_{rescue} from the approximate formula (eq. (3)), with good agreement. Parameters: $N = 10^4$; $\lambda_w = \lambda_a = \lambda_m = 0.14$; (B) $\mu_w = 0.17$; $\mu_m = 0.13$; $u = 10^{-2}$; $v = 10^{-7}$.




Figure 7: Evolutionary rescue time. Shown is the mean time for appearance of a resistance mutation the leads to evolutionary rescue **(left)** with ($u > 0$) and **(right)** without ($u = 0$ aneuploidy). Our inhomogeneous Poisson-process approximations (solid blue lines, right: eq. (11), left: eq. (16)) is in agreement with simulation results (orange markers with 95% CI). Our 1st-order (dashed red lines, right: eq. (12), left: eq. (17)) and 2nd-order (green line, left: eq. (18)) approximations work well when the initial tumor size is large (here $> 10^8$ cells). Parameters: $\lambda_w = \lambda_a = \lambda_m = 0.14$; $\mu_w = 0.17$; (A) $\mu_a = 0.145$; $\mu_m = 0.13$; $u = 10^{-2}$; $v = 10^{-7}$.




Figure 8: Ratio of evolutionary rescue time with and without aneuploidy. The ratio of the mean time to appearance of a resistance mutation that leads to evolutionary rescue with ($u > 0$) and without ($u = 0$) aneuploidy for variable initial tumor sizes (eq. (20)) when aneuploidy provides tolerance to the drug ($\Delta_a \ll 0$). When the initial tumor size is not large ($< 10^8$), aneuploidy can decrease the rescue time by 10-100-fold. *I THINK THERE IS A MISTAKE IN THE BLUE LINE*